The powder should dissolve completely into a clear, colorless solution
Evidence base: Most data comes from preclinical studies and small clinical trials
The results of the TIMES project confirmed the differentiated characteristics of imeglimin, showing that imeglimin has a dual mechanism of action to increase insulin secretion and improve insulin sensitivity, and it shows an increased hypoglycemic effect when combined with drugs with complementary mechanisms of action, including DPP-4 inhibition Agents, SGLT2 inhibitors, biguanides, sulfonylurea drugs, gleneides, alpha-glucosidase inhibitors, thiazolidine drugs, GLP1 receptor agonists
A clinical evaluation, any laboratory work your prescriber orders, and ongoing follow-up, since the labels direct that treatment response and tolerability be considered when selecting a maintenance dosage
Tick to bundle & save: Pay by Bank Powered by Fena FCA-regulated open banking authenticated in your banking app, no card details shared